Literature DB >> 28530220

Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.

Charlotte F Kweldam1, Intan P Kümmerlin1, Daan Nieboer2, Ewout W Steyerberg2, Chris H Bangma3, Luca Incrocci4, Theodorus H van der Kwast5, Monique J Roobol3, Geert J van Leenders1.   

Abstract

Relative increase of grade 4 and presence of invasive cribriform and/or intraductal carcinoma have individually been associated with adverse outcome of Gleason score 7 (GS 7) prostate cancer. The objective of this study was to investigate the relation of Gleason grade 4 tumor percentage (%GG4) and invasive cribriform and/or intraductal carcinoma in GS 3+4=7 prostate cancer biopsies. We reviewed 1031 prostate cancer biopsies from the European Randomized Study of Screening for Prostate Cancer. In total 370 men had G3+4=7. The relation of invasive cribriform and/or intraductal carcinoma and %GG4 with biochemical recurrence-free survival (BCRFS) after radical prostatectomy (n=146) and radiation therapy (n=195) was analyzed using Cox regression. Invasive cribriform and/or intraductal carcinoma occurred in 7/121 (6%) patients with 1-10% GG4, 29/131 (22%) with 10-25%, and 52/118 (44%) with 25-50% GG4 (P<0.001). In crude analysis, both invasive cribriform and/or intraductal carcinoma (HR 2.72; 95% CI: 1.33-5.95; P=0.006) and 10-50% GG4 (HR 2.43; 95% CI: 1.10-5.37; P=0.03) were associated with BCRFS after prostatectomy. In adjusted analysis, invasive cribriform and/or intraductal carcinoma was an independent predictor for BCRFS (HR 2.40; 95% CI: 1.03-5.60; P=0.04) after prostatectomy, whereas percentage %GG4 (HR 1.00; 95% CI: 0.97-1.03; P=0.80) was not. While invasive cribriform and/or intraductal carcinoma (HR 2.58; 95% CI: 1.59-4.21; P<0.001) performed better than 10-50% GG4 (HR 1.24; 95% CI: 0.67-2.29; P=0.49) for prediction of BCRFS after radiation therapy, both parameters were insignificant in analysis adjusted for prostate-specific antigen (P=0.001), positive biopsies (P<0.001) and tumor volume (P=0.05). In conclusion, increased %GG4 is associated with invasive cribriform and/or intraductal carcinoma in GS 3+4=7 prostate cancer biopsies. Invasive cribriform and/or intraductal carcinoma is an independent parameter for BCR after prostatectomy, whereas %GG4 is not. The presence of invasive cribriform and/or intraductal carcinoma has to be included in pathology reports and should act as exclusion criterion for active surveillance.

Entities:  

Mesh:

Year:  2017        PMID: 28530220     DOI: 10.1038/modpathol.2017.29

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  28 in total

1.  Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence.

Authors:  Adam I Cole; Todd M Morgan; Daniel E Spratt; Ganesh S Palapattu; Chang He; Scott A Tomlins; Alon Z Weizer; Felix Y Feng; Angela Wu; Javed Siddiqui; Arul M Chinnaiyan; Jeffrey S Montgomery; Lakshmi P Kunju; David C Miller; Brent K Hollenbeck; John T Wei; Rohit Mehra
Journal:  J Urol       Date:  2016-02-23       Impact factor: 7.450

2.  Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort.

Authors:  Dominique Trudel; Michelle R Downes; Jenna Sykes; Ken J Kron; John Trachtenberg; Theodorus H van der Kwast
Journal:  Eur J Cancer       Date:  2014-04-03       Impact factor: 9.162

3.  Should we replace the Gleason score with the amount of high-grade prostate cancer?

Authors:  André N Vis; Stijn Roemeling; Ries Kranse; Fritz H Schröder; Theo H van der Kwast
Journal:  Eur Urol       Date:  2006-08-15       Impact factor: 20.096

Review 4.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.

Authors:  Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

5.  Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.

Authors:  Nathan Perlis; Rashid Sayyid; Andrew Evans; Theodorus Van Der Kwast; Ants Toi; Antonio Finelli; Girish Kulkarni; Rob Hamilton; Alexandre R Zlotta; John Trachtenberg; Sangeet Ghai; Neil E Fleshner
Journal:  J Urol       Date:  2016-07-22       Impact factor: 7.450

6.  Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.

Authors:  Daniel T Keefe; Nicola Schieda; Soufiane El Hallani; Rodney H Breau; Chris Morash; Susan J Robertson; Kien T Mai; Eric C Belanger; Trevor A Flood
Journal:  Virchows Arch       Date:  2015-07-31       Impact factor: 4.064

7.  Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.

Authors:  Charlotte F Kweldam; Intan P Kümmerlin; Daan Nieboer; Esther I Verhoef; Ewout W Steyerberg; Theodorus H van der Kwast; Monique J Roobol; Geert J van Leenders
Journal:  Mod Pathol       Date:  2016-03-04       Impact factor: 7.842

8.  Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists.

Authors:  Charlotte F Kweldam; Daan Nieboer; Ferran Algaba; Mahul B Amin; Dan M Berney; Athanase Billis; David G Bostwick; Lukas Bubendorf; Liang Cheng; Eva Compérat; Brett Delahunt; Lars Egevad; Andrew J Evans; Donna E Hansel; Peter A Humphrey; Glen Kristiansen; Theodorus H van der Kwast; Cristina Magi-Galluzzi; Rodolfo Montironi; George J Netto; Hemamali Samaratunga; John R Srigley; Puay H Tan; Murali Varma; Ming Zhou; Geert J L H van Leenders
Journal:  Histopathology       Date:  2016-05-24       Impact factor: 5.087

9.  Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.

Authors:  Toshihiro Yamamoto; H Bindu Musunuru; Danny Vesprini; Liying Zhang; Gabriella Ghanem; Andrew Loblaw; Laurence Klotz
Journal:  J Urol       Date:  2015-12-18       Impact factor: 7.450

10.  Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens.

Authors:  Guido Sauter; Stefan Steurer; Till Sebastian Clauditz; Till Krech; Corinna Wittmer; Florian Lutz; Maximilian Lennartz; Tim Janssen; Nayira Hakimi; Ronald Simon; Mareike von Petersdorff-Campen; Frank Jacobsen; Katharina von Loga; Waldemar Wilczak; Sarah Minner; Maria Christina Tsourlakis; Viktoria Chirico; Alexander Haese; Hans Heinzer; Burkhard Beyer; Markus Graefen; Uwe Michl; Georg Salomon; Thomas Steuber; Lars Henrik Budäus; Elena Hekeler; Julia Malsy-Mink; Sven Kutzera; Christoph Fraune; Cosima Göbel; Hartwig Huland; Thorsten Schlomm
Journal:  Eur Urol       Date:  2015-11-02       Impact factor: 20.096

View more
  19 in total

1.  Comedonecrosis Revisited: Strong Association With Intraductal Carcinoma of the Prostate.

Authors:  Samson W Fine; Hikmat A Al-Ahmadie; Ying-Bei Chen; Anuradha Gopalan; Satish K Tickoo; Victor E Reuter
Journal:  Am J Surg Pathol       Date:  2018-08       Impact factor: 6.394

2.  Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier.

Authors:  Alexander S Taylor; Todd M Morgan; David G Wallington; Arul M Chinnaiyan; Daniel E Spratt; Rohit Mehra
Journal:  Prostate       Date:  2019-11-18       Impact factor: 4.104

3.  AI Model for Prostate Biopsies Predicts Cancer Survival.

Authors:  Kevin Sandeman; Sami Blom; Ville Koponen; Anniina Manninen; Juuso Juhila; Antti Rannikko; Tuomas Ropponen; Tuomas Mirtti
Journal:  Diagnostics (Basel)       Date:  2022-04-20

4.  Evaluation of tumor morphologies and association with biochemical recurrence after radical prostatectomy in grade group 5 prostate cancer.

Authors:  Trevor A Flood; Nicola Schieda; Jordan Sim; Rodney H Breau; Chris Morash; Eric C Belanger; Susan J Robertson
Journal:  Virchows Arch       Date:  2017-10-03       Impact factor: 4.064

Review 5.  Cribriform Prostate Cancer: Clinical Pathologic and Molecular Considerations.

Authors:  Amanda B Hesterberg; Jennifer B Gordetsky; Paula J Hurley
Journal:  Urology       Date:  2021-05-28       Impact factor: 2.633

Review 6.  On cribriform prostate cancer.

Authors:  Charlotte F Kweldam; Theodorus van der Kwast; Geert J van Leenders
Journal:  Transl Androl Urol       Date:  2018-02

7.  The percentage of high-grade prostatic adenocarcinoma in prostate biopsies significantly improves on Grade Groups in the prediction of prostate cancer death.

Authors:  Daniel M Berney; Luis Beltran; Holly Sandu; Geraldine Soosay; Henrik Møller; Peter Scardino; Jacqueline Murphy; Amar Ahmad; Jack Cuzick
Journal:  Histopathology       Date:  2019-08-13       Impact factor: 5.087

Review 8.  Active surveillance for prostate cancer.

Authors:  Daniela K Shill; Monique J Roobol; Behfar Ehdaie; Andrew J Vickers; Sigrid V Carlsson
Journal:  Transl Androl Urol       Date:  2021-06

9.  The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma.

Authors:  Geert J L H van Leenders; Theodorus H van der Kwast; David J Grignon; Andrew J Evans; Glen Kristiansen; Charlotte F Kweldam; Geert Litjens; Jesse K McKenney; Jonathan Melamed; Nicholas Mottet; Gladell P Paner; Hemamali Samaratunga; Ivo G Schoots; Jeffry P Simko; Toyonori Tsuzuki; Murali Varma; Anne Y Warren; Thomas M Wheeler; Sean R Williamson; Kenneth A Iczkowski
Journal:  Am J Surg Pathol       Date:  2020-08       Impact factor: 6.298

10.  Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis.

Authors:  Eva Hollemans; Esther I Verhoef; Chris H Bangma; John Rietbergen; Jozien Helleman; Monique J Roobol; Geert J L H van Leenders
Journal:  Mod Pathol       Date:  2018-10-22       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.